These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7893 related articles for article (PubMed ID: 24176884)
1. Who benefits most from adjuvant interferon treatment for melanoma? Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Kirkwood JM; Tarhini AA Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880 [TBL] [Abstract][Full Text] [Related]
3. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma. Wilson LS; Reyes CM; Lu C; Lu M; Yen C Melanoma Res; 2002 Dec; 12(6):607-17. PubMed ID: 12459651 [TBL] [Abstract][Full Text] [Related]
4. Current therapy of cutaneous melanoma. Mays SR; Nelson BR Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545 [TBL] [Abstract][Full Text] [Related]
5. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Crott R; Ali F; Burdette-Radoux S Value Health; 2004; 7(4):423-32. PubMed ID: 15449634 [TBL] [Abstract][Full Text] [Related]
6. Current management of melanoma: benefits of surgical staging and adjuvant therapy. McMasters KM; Swetter SM J Surg Oncol; 2003 Mar; 82(3):209-16. PubMed ID: 12619066 [TBL] [Abstract][Full Text] [Related]
8. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma. Agarwala SS Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109 [TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Crott R Pharmacoeconomics; 2004; 22(9):569-80. PubMed ID: 15209526 [TBL] [Abstract][Full Text] [Related]
10. Update on adjuvant interferon therapy for high-risk melanoma. Agarwala SS; Kirkwood JM Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946 [TBL] [Abstract][Full Text] [Related]
11. Update on the role of adjuvant interferon for high risk melanoma. Agarwala SS; Kirkwood JM Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931 [TBL] [Abstract][Full Text] [Related]
12. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846 [TBL] [Abstract][Full Text] [Related]
17. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse. Gale DM; Kiley KE Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Bajetta E Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604 [No Abstract] [Full Text] [Related]
19. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Dixon S; Walters SJ; Turner L; Hancock BW Br J Cancer; 2006 Feb; 94(4):492-8. PubMed ID: 16449995 [TBL] [Abstract][Full Text] [Related]
20. [Interferons and malignant melanoma]. Dreno B Rev Med Interne; 2002 Nov; 23 Suppl 4():489s-493s. PubMed ID: 12481404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]